CD27 and neoplasm: Many immunomodulators, such as indoleamine 2,3‐dioxygenase (IDO) inhibitors, STAT3 inhibitors, TGF‐β inhibitors, CD137 agonists, and CD27 agonists, also have the potential to reshape the tumor immune microenvironment.[14] It remains unclear whether these immunomodulators play roles similar to those of R848 and aOX40, and further exploration is needed in the future to expand the strategic application of this work.